Xponance Inc. Increases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Xponance Inc. lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,169 shares of the pharmaceutical company's stock after buying an additional 662 shares during the quarter. Xponance Inc.'s holdings in Vertex Pharmaceuticals were worth $23,838,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Sage Rhino Capital LLC purchased a new stake in shares of Vertex Pharmaceuticals during the first quarter worth approximately $220,000. Fidelis Capital Partners LLC increased its position in shares of Vertex Pharmaceuticals by 1.5% during the first quarter. Fidelis Capital Partners LLC now owns 5,604 shares of the pharmaceutical company's stock worth $2,767,000 after purchasing an additional 84 shares in the last quarter. Genus Capital Management Inc. purchased a new stake in shares of Vertex Pharmaceuticals during the first quarter worth approximately $2,317,000. Joseph Group Capital Management increased its position in shares of Vertex Pharmaceuticals by 11.0% during the first quarter. Joseph Group Capital Management now owns 7,126 shares of the pharmaceutical company's stock worth $3,455,000 after purchasing an additional 704 shares in the last quarter. Finally, MJP Associates Inc. ADV purchased a new stake in shares of Vertex Pharmaceuticals during the first quarter worth approximately $226,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Trading Down 2.2%

VRTX traded down $10.68 during mid-day trading on Friday, hitting $468.85. 892,738 shares of the stock were exchanged, compared to its average volume of 1,424,305. The firm's fifty day moving average is $447.71 and its two-hundred day moving average is $460.40. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01. The company has a market cap of $120.40 billion, a PE ratio of -119.60 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same period in the previous year, the company posted $4.76 EPS. Vertex Pharmaceuticals's revenue was up 2.6% on a year-over-year basis. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on VRTX. Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, June 23rd. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Leerink Partnrs cut Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. upped their target price on Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $511.62.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.